VERASTEM INC. news, videos and press releases - Page 2
For more news please use our advanced search feature.
VERASTEM INC. - More news...
VERASTEM INC. - More news...
- Verastem Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress
- Verastem Oncology Outlines Key 2023 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib as a Backbone of Therapy for RAS Pathway-Driven Cancers
- Verastem Oncology Announces Up to $60 Million Private Placement Offering of Series B Convertible Preferred Stock
- Verastem Oncology Announces Positive Data and Regulatory Update from Planned Interim Analysis of Registration-Directed Phase 2 RAMP-201 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
- Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Verastem Oncology Appoints Rob Gagnon to Board of Directors
- Verastem Oncology Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
- Verastem Oncology Appoints Anil Kapur to Board of Directors
- Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Verastem Oncology Announces RAMP VS-6766 Clinical Trials and Corporate Updates
- Verastem Oncology Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress
- Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Verastem Oncology Provides Update on RAMP 201 Study Evaluating VS-6766 ± Defactinib in Low-Grade Serous Ovarian Cancer
- Verastem Oncology Awarded Pancreatic Cancer Action Network’s First Therapeutic Accelerator Award to Evaluate the Combination of VS-6766 and Defactinib in Front-Line Metastatic Pancreatic Cancer
- Verastem Oncology Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress
- Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Verastem Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company Progress
- Verastem Oncology Provides Financial Update to Support Development of VS-6766 and Defactinib in RAS Pathway-Driven Tumors
- Verastem Oncology Names Preeminent Oncology Researcher Channing Der, PhD, to its Scientific Advisory Board
- Verastem Oncology Outlines Key 2022 Strategic Priorities and Upcoming Catalysts for Advancing VS-6766 as a Backbone of Therapy for RAS Pathway-Driven Cancers
- Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Verastem Oncology to Participate in Upcoming Investor Conferences
- Verastem Oncology to Present at the Jefferies London Healthcare Conference
- Verastem Oncology Reports Third Quarter 2021 Financial Results and Highlights Recent Company Progress
- Verastem Oncology Appoints Michelle Robertson to Board of Directors
- Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Verastem Oncology Appoints Louis J. Denis, M.D., as Chief Medical Officer
- Verastem Oncology Announces Updated Investigator-Sponsored Phase 1/2 FRAME Study Data of VS-6766 with Defactinib in Low-Grade Serous Ovarian Cancer Showing Encouraging Response Rates and Progression-Free Survival Presented at ESMO 2021
- Verastem Oncology to Present at Upcoming Investor Conferences
- Verastem Oncology Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress
